Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used a...
Main Authors: | Hanne Lind, Sofia R Gameiro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e000461.full |
Similar Items
-
Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma
by: Yaru HUANG, et al.
Published: (2021-06-01) -
Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
by: Kazuhiro Kitajima, et al.
Published: (2021-03-01) -
Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
by: Yoshie Yoshikawa, et al.
Published: (2020-12-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
by: Roger Y. Kim, MD, et al.
Published: (2021-06-01) -
Treatment of malignant pleural mesothelioma: current status and future directions
by: X. Dhalluin, et al.
Published: (2016-01-01)